UPCC 09517: Phase II study of Pembrolizumab and Itacitinib (INCB039110) for First Line Treatment of Metastatic Non-Small Cell Lung Cancer Expressing PD-L1

Brief description of study

The main purpose of this study is to examine the efficacy of adding itacitinib (also known as INCB039110) to pembrolizumab in patients with previously untreated metastatic non-small cell lung cancer.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    lung cancer
  • Age: - 99 Years
  • Gender: All
Updated on 29 Jan 2020. Study ID: 828910

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center